ライフサイエンスコーパス: neutropenic

1 Most patients (90%) were not neutropenic.

2 Four patients were neutropenic.

3 tients developed evidence of infection while neutropenic.

4 transcriptional repressor protein GFI-1 are neutropenic.

5 repressor oncoprotein Gfi1 are unexpectedly neutropenic.

6 PM was diagnosed, all patients but one were neutropenic.

7 We find no role in virulence, however, among neutropenic and corticosteroid-suppressed mice with DC r

8 Efficacy is retained in neutropenic and corticosteroid-treated mice.

9 it(W/W-v) mice are MC-deficient, anemic, and neutropenic and have normal T cell compartments.

10 In both neutropenic and neutrophil-replete animals, the local re

11 terization revealed that these patients were neutropenic and NK cell deficient.

12 (DC) induced by intravenous infection among neutropenic and nonimmunosuppressed mice, as well as in

13 (levofloxacin) had 100% survivorship in both neutropenic and nonneutropenic groups.

14 There was no difference between the neutropenic and nonneutropenic patients in need of inten

15 e risk groups, the most vulnerable hosts are neutropenic and patients who are mechanically ventilated

16 t androgen receptor knockout (ARKO) mice are neutropenic and susceptible to acute bacterial infection

17 that gene-targeted Gfi-1-deficient mice are neutropenic and that Gfi-1 mutations cause human neutrop

18 e to ehrlichiosis, both dogs were anemic and neutropenic and the Thai dog was thrombocytopenic.

19 dels were that the animals were not rendered neutropenic and they did not receive porcine mucin with

20 Median age was 59 years; 19% were neutropenic, and 22% were in an intensive care unit on t

21 Among these, 88% (22/25) were neutropenic, and 76% (19/25) had leukemia.

22 r syngeneic BMT, B6D2F(1) mice are no longer neutropenic, and by 3 wk, they demonstrate complete reco

23 Neutropenic animals and liver macrophage (Kupffer cell)

24 Infection of neutropenic animals resulted in increased levels of viru

25 of lung dendritic cells was more immature in neutropenic animals than in nonneutropenic mice exposed

26 These findings coincided with the fact that neutropenic animals were more susceptible to A. hydrophi

27 mice with adhesion molecule deletions and in neutropenic animals.

28 he optimal exposures initially identified in neutropenic animals.

29 ork was undertaken in neutropenic versus non-neutropenic animals.

30 e to greatly elevated lung TNF expression in neutropenic as compared with nonneutropenic animals.

31 seases, including infective endocarditis and neutropenic bacteremia.

32 inyl alcohol sponge wound model in mice made neutropenic by anti-Gr-1 Ab, as well as in cell culture.

33 Abdominal pain in neutropenic cancer patients presents a unique clinical c

34 This included 66,106 adult neutropenic cancer patients with 88,074 hospitalizations

35 Thromboembolism is frequent in hospitalized neutropenic cancer patients, including in perceived low-

36 Neutropenic colitis is characterized by right-sided colo

37 he myeloid growth factors reduce the risk of neutropenic complications and may facilitate delivered d

38 myeloid growth factors to reduce the risk of neutropenic complications and sustain dose intensity con

39 Neutropenic complications including febrile neutropenia

40 nd cost of these agents in the prevention of neutropenic complications including febrile neutropenia.

41 rade 3 to 4 toxicities were hematologic, few neutropenic complications resulted.

42 t variables that increase individual risk of neutropenic complications.

43 bacterial concentration is very high, under neutropenic conditions or when there is neutrophil dysfu

44 Thus, targeting IL-4 might be beneficial in neutropenic conditions with increased susceptibility to

45 In patients treated in a PE, a neutropenic diet did not prevent major infection or deat

46 A neutropenic diet is often used to prevent infection in p

47 ichia mikurensis" infection in a chronically neutropenic dog from Germany was confirmed by DNA sequen

48 more age-dependent, associated with a modest neutropenic effect (9%, P = .012), demonstrated familial

49 t frequent causes of the abdominal pain were neutropenic enterocolitis (28%) and small bowel obstruct

50 Neutropenic enterocolitis (NEC) is a life-threatening di

51 s of this entity that can help differentiate neutropenic enterocolitis from other gastrointestinal co

52 Neutropenic enterocolitis is a serious, potentially leth

53 Neutropenic enterocolitis, also referred to as typhlitis

54 sis, leukemic meningitis, neutropenic fever, neutropenic enterocolitis, and transfussion-associated G

55 , diagnosis, and management of patients with neutropenic enterocolitis.

56 tions did not alter significantly during the neutropenic episode.

57 e frequency, duration, and causes of febrile neutropenic episodes were recorded, and MBL genotype and

58 ient treatment is standard to manage febrile neutropenic episodes, although carefully selected patien

59 Acute toxicities during TPE included neutropenic fever (10%) and during XPE, grade 3 or 4 ora

60 de >/=3 adverse events were pneumonia (20%), neutropenic fever (11%), and diarrhea (6%).

61 related to neutropenia present at baseline: neutropenic fever (13 of 25 subjects) and septic death (

62 (3.3% v 0.0%; P =.004), hospitalizations for neutropenic fever (13.4% v 1.5%; P <.001), hospitalizati

63 events included fatigue (5%), vomiting (2%), neutropenic fever (2%), and neutropenia (2%).

64 ), thrombocytopenia (12%), anemia (12%), and neutropenic fever (2%).

65 bocytopenia: grade 3, 26%; grade 4, 3%), but neutropenic fever (6%) and bleeding events (0%) were rar

66 s, moderate to severe neutropenia (38%), and neutropenic fever (6%).

67 rade 3 hypersensitivity reaction (n = 1) and neutropenic fever (n = 1), both at 10 mg/kg.

68 common grade 3-4 adverse events overall were neutropenic fever (n=27) and pneumonia (n=18).

69 s was observed after 4%, infection after 3%, neutropenic fever after 6%, neutrophils less than 100/mi

70 microg/kg did not reduce the probability of neutropenic fever after high-dose paclitaxel.

71 The incidence of neutropenic fever after the first cycle of paclitaxel 25

72 ohort, these infections were associated with neutropenic fever from an enteric source, and most isola

73 ogic or electrolyte abnormalities, including neutropenic fever in 18%.

74 ppression was the major adverse effect, with neutropenic fever in 28 (23%) of 124 courses of therapy.

75 However, neither neutropenic fever nor episodes of bleeding were major oc

76 Major infections or neutropenic fever occurred in 13% of patients.

77 There was no neutropenic fever or neutropenic sepsis.

78 Neutropenic fever requiring hospitalization occurred in

79 All had neutropenic fever with symptoms of mucositis and/or ente

80 16 patients [50%], with six [19%] developing neutropenic fever).

81 c: grade 3/4 neutropenia, four patients (one neutropenic fever); two patients had grade 3 thrombocyto

82 well tolerated with anticipated cytopenias, neutropenic fever, and disease-related fever, diarrhea,

83 herapy was well tolerated, with transfusion, neutropenic fever, and infection remaining the most freq

84 -associated thrombosis, leukemic meningitis, neutropenic fever, neutropenic enterocolitis, and transf

85 with bleeding, grade 3 or 4 renal toxicity, neutropenic fever, or mucositis) was observed in 9.3% of

86 lantation, 13 patients were hospitalized for neutropenic fever, thrombocytopenia, or both.

87 tment breaks were mediport complications and neutropenic fever, which occurred mostly at that dose le

88 ms commonly used in the empiric treatment of neutropenic fever.

89 ncluded one grade 4 diarrhea and one grade 4 neutropenic fever.

90 nd 3% of patients receiving TAP experiencing neutropenic fever.

91 ut was manageable with only a single case of neutropenic fever.

92 amycin-piperacillin for empirical therapy of neutropenic fever.

93 nsisting of thrombocytopenia associated with neutropenic fever.

94 3, n = 20 [33%]; grade 4, n = 2 [3%]) but no neutropenic fever.

95 owever, it did not increase the incidence of neutropenic fever.

96 No patient required hospitalization for neutropenic fever.

97 adverse events that was most pronounced for neutropenic fever/infections and gastrointestinal events

98 on therapy, whereas myalgia, arthralgia, and neutropenic fever/sepsis were more common with single-ag

99 nia (P <.0001) leading to significantly less neutropenic fever/sepsis.

100 Grade 3 or 4 neutropenic fevers (P=0.01), nausea and vomiting (P<0.00

101 es were observed in 10% of patients, with no neutropenic fevers or treatment-related death.

102 transfusion of conditioned neutrophils in a neutropenic guinea pig model increased bacterial clearan

103 An established neutropenic guinea pig model of IPA caused by Aspergillu

104 llin/tazobactam alone in febrile, high-risk, neutropenic hematologic patients with cancer.

105 as crucial innate cellular effectors in the neutropenic host after active immunization.

106 lera toxin was found to be protective to the neutropenic host, and this phenotype can be replicated b

107 lethal bacterial infection in the profoundly neutropenic host.

108 the disease burden in immunocompromised and neutropenic hosts and causes serious congenital complica

109 ts, were found to accumulate in the lungs of neutropenic hosts challenged with killed or live-attenua

110 TRAIL-based therapy in neutropenic hosts may represent a novel antibacterial tr

111 The mechanism of this accumulation in neutropenic hosts was found to be augmented influx of DC

112 sis, a prototypic opportunistic infection in neutropenic hosts, is associated with marked accumulatio

113 negative patients, including pregnant women, neutropenic hosts, solid-organ or stem cell transplant r

114 DC traffic and phenotype and is specific to neutropenic hosts.

115 or the treatment of refractory infections in neutropenic hosts.

116 strategy for the prevention of infection in neutropenic hosts.

117 minated candidiasis as once-daily therapy in neutropenic hosts.

118 g following low dose spore inhalation in non-neutropenic hosts.

119 ctable in mouse lungs, serum and BALF during neutropenic IA, suggesting that GT may be useful to diag

120 However, not all neutropenic individuals develop infections, so the abili

121 The SIGNIFICANT (Simple Investigation in Neutropenic Individuals of the Frequency of Infection af

122 s and elevated expression of ELA2 in vivo in neutropenic individuals that GFI1 represses ELA2, linkin

123 rcellular adhesion molecule (ICAM)-1-/-, and neutropenic-induced mice were subjected to 70% hepatecto

124 Mice were made neutropenic; infected or not with Staphylococcus aureus,

125 ged grade 4 neutropenia (n = 4), and grade 5 neutropenic infection (n = 1).

126 < .001), hand-foot syndrome (P < .001), and neutropenic infection (P < .001).

127 h 25 mg lenalidomide developed a grade 4 non-neutropenic infection and died.

128 ns controversial for patients at low risk of neutropenic infection.

129 rse events were leukopenia (eight [32%]) and neutropenic infections (five [20%]).

130 of 1.9% (64 of 3,402) was mainly related to neutropenic infections (n = 56; 87.5%).

131 icant difference in toxicities was decreased neutropenic infections in patients treated with nelarabi

132 pecific defense mechanisms in the context of neutropenic infections is limited.

133 in source of early IFN-gamma in the lungs in neutropenic invasive aspergillosis, and this is an impor

134 Finally, in the context of neutropenic invasive aspergillosis, depletion of DCs res

135 In the particular setting of neutropenic leukemia patients with pulmonary infection,

136 Enrichment of GT in Aspergillus-infected neutropenic lung correlated with fungal burden and hypha

137 Interestingly, neutropenic lysozyme 2-diphtheria toxin A mice exhibited

138 Anti-PMN-treated mice became neutropenic (mean, 349 cells/microL), experiencing an 84

139 ony-stimulating factor increased survival of neutropenic mice after i.n. P. aeruginosa inoculation.

140 rmal mice but was outcompeted by MGAS2221 in neutropenic mice and had enhancements in expression of v

141 whereas the differences observed between the neutropenic mice and the saline-pretreated controls were

142 ion, myelin loss, and AQP4 loss in brains of neutropenic mice at 24 hours and 7 days, and increased s

143 e virulence defect was partially restored in neutropenic mice by adding gentamicin, an antibiotic tha

144 Wounds in neutropenic mice contained 100-fold fewer neutrophils th

145 Wound fluids from neutropenic mice contained 68% more TNF-alpha, 168% more

146 f granulocytes yielded 90% survivorship; all neutropenic mice died after the termination of treatment

147 48 mg/kg every 24 h in cohorts of normal and neutropenic mice for 5 days.

148 tion, 25 microg of the MAb protected 100% of neutropenic mice from fatal P. aeruginosa sepsis.

149 In neutropenic mice infected with wild-type A. fumigatus, i

150 alpha, suggesting the decreased survival in neutropenic mice is due to systemic shock.

151 Most importantly, neutropenic mice lacking neutrophil-derived TRAIL were p

152 An adoptive transfer of dendritic cells into neutropenic mice provided a protective effect during inv

153 Because identical ischemic injury in neutropenic mice resulted in milder renal insufficiency

154 At a high dose, neutropenic mice showed increased rates of survival comp

155 Non-neutropenic mice that were immunosuppressed with cortiso

156 However, the bacterial load in the neutropenic mice was comparable to that of the saline-pr

157 Simulation of this dose in neutropenic mice was highly effective in methicillin-sen

158 more resistant to Salmonella infection, but neutropenic mice were not protected by casein.

159 res of lung injury in wild-type mice whereas neutropenic mice were protected from such injury.

160 We found that, in the lungs of neutropenic mice with invasive aspergillosis, NK cells w

161 rked induction of MCP-1/CCL2 in the lungs of neutropenic mice with invasive aspergillosis.

162 ciated with airway eosinophil recruitment in neutropenic mice with invasive pulmonary aspergillosis (

163 ATAK cells improved the survival of neutropenic mice with lethal disseminated candidiasis an

164 hen administered to diabetic ketoacidotic or neutropenic mice with mucormycosis, deferasirox signific

165 or only the first 24 h, or using genetically neutropenic mice), the cellular responses increased seve

166 In uninfected neutropenic mice, ATAK cells spread from the mesentery i

167 mAb-induced tumor reduction, abolished in neutropenic mice, could be restored in FcgammaR-deficien

168 mutational analysis, we demonstrate that, in neutropenic mice, elimination of the A. nidulans pH-resp

169 In neutropenic mice, intranasal (i.n.) doses of P. aerugino

170 In neutropenic mice, the LPS-induced NF-kB activation and T

171 accessory toxins in virulence is negated in neutropenic mice, which is consistent with a role of acc

172 s disease (CGD), hydrocortisone-treated, and neutropenic mice.

173 that effectively treat lethal infections in neutropenic mice.

174 , like wild-type bacteria, it was lethal for neutropenic mice.

175 Ag-specific T cells and DCs was improved in neutropenic mice.

176 protective during invasive aspergillosis in neutropenic mice.

177 corticosteroids, but had normal virulence in neutropenic mice.

178 % for normal mice and 80%, 100%, and 70% for neutropenic mice.

179 , during pulmonary invasive aspergillosis in neutropenic mice.

180 rimental invasive pulmonary aspergillosis in neutropenic mice.

181 antifungal response against A. fumigatus in neutropenic mice.

182 iously shown to be required for virulence in neutropenic mice.

183 protective during invasive aspergillosis in neutropenic mice.

184 sponse in the skin and was fully virulent in neutropenic mice.

185 utrophil-depleting antibodies or genetically neutropenic mice.

186 sing ace2Delta Candida glabrata infection in neutropenic mice.

187 abscesses and decreased disease severity in neutropenic mice.

188 s detected in 71% of sera and 50% of BALF of neutropenic mice; neither was detected in serum/BALF of

189 ced neutrophils (AINs) either in vitro or in neutropenic mouse model displayed strong bactericidal ac

190 enesis by A fumigatus both in vitro and in a neutropenic mouse model is mediated through secondary me

191 ted and reduced pulmonary fungal burden in a neutropenic mouse model of invasive aspergillosis.

192 In a neutropenic mouse model of IPA, treatment with posaconaz

193 Here, we show in a neutropenic mouse model that immunity induced by mucosal

194 al experiments (n = 6, including 5 using the neutropenic mouse thigh infection model), and clinical s

195 aspergillosis, we used a well-characterized neutropenic murine model.

196 Subsequently, a neutropenic murine pneumonia model with simulated clinic

197 ted combinations were further validated in a neutropenic murine pneumonia model, using human-like dos

198 dynamically linked variable in the S. aureus neutropenic murine pneumonia model; the fAUC/MIC ratio r

199 In the Staphylococcus aureus neutropenic murine thigh-infection model, the ratio of t

200 constructed and found to be attenuated in a neutropenic, murine model of pulmonary infection.

201 Febrile (temperature >/= 38 degrees C), neutropenic (neutrophil level < 1 x 10(9) cells/L) hospi

202 r WT thymocytes correct neutrophil counts in neutropenic nude mice.

203 Athymic nude mice are neutropenic or have near-normal neutrophil counts, depen

204 ad attenuated virulence, unless animals were neutropenic or lysozyme deficient.

205 leukocytes; to produce disease in wild-type, neutropenic, or lysozyme-deficient rodents; and to induc

206 pment of fever and/or infections in afebrile neutropenic outpatients and recovery without complicatio

207 Secondary outcomes included: in afebrile neutropenic outpatients, infection-related mortality; in

208 mplications and overall mortality in febrile neutropenic outpatients.

209 gh-dose daptomycin (DAP) therapy failed in a neutropenic patient with bloodstream infection caused by

210 superiority trial, adult, febrile, high-risk neutropenic patients (FhrNPs) with hematologic malignanc

211 of A. fumigatus without developing disease, neutropenic patients and those receiving immunosuppressi

212 eages, and a partial response was defined in neutropenic patients as 100% increase in the absolute ne

213 ing of anti-gram-positive therapy to febrile neutropenic patients at risk of serious beta-lactam-resi

214 response to the invading fungi, not only in neutropenic patients but also in patients with normal or

215 Neutropenic patients continue to be at increased risk fo

216 Abdominal pain as a symptom in neutropenic patients continues to be a diagnostic and th

217 Data from 569 unique cases of VGS BSI in neutropenic patients from 2000 to 2010 at the MD Anderso

218 miting empiric anti-gram-positive therapy to neutropenic patients having at least 1 of these 3 risk f

219 is efficacious and safe in low-risk febrile neutropenic patients identified with the help of the MAS

220 Febrile neutropenic patients should receive initial doses of emp

221 For example, the profound susceptibility of neutropenic patients to infection marks neutrophils (the

222 STR occurred only in neutropenic patients transfused with high bacterial load

223 al infections are accordingly encountered in neutropenic patients undergoing chemotherapy.

224 of 52 VS strains isolated from the blood of neutropenic patients was used to demonstrate the ability

225 Neutropenic patients were less likely to have a single p

226 and PCT levels were significantly higher in neutropenic patients with BSIs than in those without doc

227 idered the standard of treatment for febrile neutropenic patients with cancer, but this approach may

228 oral combination therapy in low-risk febrile neutropenic patients with cancer.

229 Neutropenic patients with fever and abdominal symptoms (

230 Furthermore, in neutropenic patients with lung injury, deterioration of

231 In neutropenic patients with severe sepsis or septic shock,

232 Granulocyte transfusions are beneficial in neutropenic patients with severe uncontrolled infection.

233 tions, especially among immunosuppressed and neutropenic patients, as well as a source of bacterial c

234 Neutropenic patients, deficient in these immune cells, a

235 ntamination of platelets resulting in STR in neutropenic patients, failure of passive surveillance to

236 In neutropenic patients, gram-negative bacterial infections

237 c infections in immunocompetent and severely neutropenic patients, respectively.

238 In neutropenic patients, we identified PRDM5 protein sequen

239 in the gastrointestinal tract, especially in neutropenic patients.

240 mbined remaining species to be isolated from neutropenic patients.

241 ause considerable morbidity and mortality in neutropenic patients.

242 s that causes life-threatening infections in neutropenic patients.

243 streptococcal endocarditis and infection in neutropenic patients.

244 ent of a rapidly fulminant shock syndrome in neutropenic patients.

245 remains common empirical therapy for febrile neutropenic patients.

246 the viridans streptococcal shock syndrome in neutropenic patients.

247 n VGS causing bloodstream infection (BSI) in neutropenic patients.

248 e bacteria causing bloodstream infections in neutropenic patients.

249 velopment of improved treatment regimens for neutropenic patients.

250 ting that GT may be useful to diagnose IA in neutropenic patients.

251 of AFI, which was successfully treated in a neutropenic pediatric patient.

252 the risk of infection is greatest during the neutropenic period immediately following transplant, pat

253 G-CSF shortened the posttransplantation neutropenic period, but did not affect days +30 and +100

254 g placebo for seven days during the expected neutropenic period.

255 f the cathelicidin gene, Cnlp, were rendered neutropenic prior to cutaneous infection.

256 c disseminated candidiasis (CDC), and from a neutropenic-rabbit model of CDC.

257 Studies in neutropenic rabbits showed that neutrophils shortened th

258 cultures in experiments using BAL fluid from neutropenic rabbits with experimentally induced IPA defi

259 n of TGF-beta observed in livers of infected neutropenic rabbits, using a neutralizing antibody that

260 sive pulmonary aspergillosis in persistently neutropenic rabbits.

261 sive pulmonary aspergillosis in persistently neutropenic rabbits.

262 and protect against microbial invasion in a neutropenic rat model of gram-negative sepsis.

263 In the neutropenic rat model, daily administration of WAY-20219

264 tested in the murine listeriosis model, the neutropenic rat Pseudomonas aeruginosa infection, and th

265 r membrane protein complex vaccine protected neutropenic rats from heterologous lethal gram-negative

266 is study, active immunization was studied in neutropenic rats infected with Pseudomonas aeruginosa, i

267 When the proteins were injected into neutropenic rats, the group injected with PEG-GCSF showe

268 was not as efficient as PEG-GCSF in treating neutropenic rats.

269 g capability (decreased bacterial burden) in neutropenic recipient mice in both peritonitis and bacte

270 e transfusions and amphotericin B in febrile neutropenic recipients may be limited by the increased i

271 morrhaged but not sham-hemorrhage animals to neutropenic recipients reproduce ALI when subsequently s

272 e effects for TH and TCH, respectively, were neutropenic-related complications, 29% and 23%; thromboc

273 XT was associated with higher GI, skin, and neutropenic-related toxicities.

274 Dose limiting toxicity comprising neutropenic sepsis (one patient) and grade 3 fatigue (on

275 n the treatment of physician's choice group (neutropenic sepsis and septic shock).

276 y dosing scheme; 2 of these patients died of neutropenic sepsis complications.

277 itabine plus cisplatin, but after two cycles neutropenic sepsis developed, which required a prolonged

278 One fatal event of neutropenic sepsis was reported in a patient allocated r

279 n the COMBO study, the MTD was 22 microg/kg (neutropenic sepsis).

280 b emtansine group [metabolic encephalopathy, neutropenic sepsis, and acute myeloid leukaemia]).

281 One fatal toxic effect, neutropenic sepsis, occurred in the primary-chemotherapy

282 One death, related to neutropenic sepsis, occurred on study.

283 CX group died of suspected treatment-related neutropenic sepsis.

284 were three treatment-related deaths owing to neutropenic sepsis.

285 There was no neutropenic fever or neutropenic sepsis.

286 ) robustly lowered the bacterial burden in a neutropenic Staphylococci murine infection model.

287 mpound 63 showed notable efficacy in a mouse neutropenic Staphylococcus aureus infection model.

288 The initial neutropenic state fostered an environment of increased d

289 nts was inhibited, without rendering animals neutropenic, suggesting an effect of G-CSF receptor bloc

290 in myeloid progenitors and become profoundly neutropenic, supporting the hypothesis that G-CSF can co

291 of inflammatory cytokines, and when rendered neutropenic the mortality difference was abrogated.

292 ioavailability and shows efficacy in a mouse neutropenic thigh infection model.

293 o PK/PD comparison of 5x and PMB in a murine neutropenic thigh model against P. aeruginosa strains wi

294 In vivo mouse systemic infection and neutropenic thigh model experimental results confirmed t

295 re quite common, whereas emergencies such as neutropenic typhlitis, pancreatitis, and acute haemolysi

296 GT levels were higher in neutropenic versus CGD or steroid-treated lungs.

297 Further work was undertaken in neutropenic versus non-neutropenic animals.

298 MAGP2-deficient mice are neutropenic, which contrasts with monocytopenia describe

299 Homozygous mutant mice are severely neutropenic with an accumulation of immature myeloid pre

300 staining was greater in cells isolated from neutropenic wounds than in those from control wounds.